These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cardiovascular risk in rheumatoid arthritis: how to lower the risk? van Breukelen-van der Stoep DF; Klop B; van Zeben D; Hazes JM; Castro Cabezas M Atherosclerosis; 2013 Nov; 231(1):163-72. PubMed ID: 24125429 [TBL] [Abstract][Full Text] [Related]
4. Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis. Cugno M; Ingegnoli F; Gualtierotti R; Fantini F Curr Vasc Pharmacol; 2010 Mar; 8(2):285-92. PubMed ID: 19485909 [TBL] [Abstract][Full Text] [Related]
5. [Chronic inflammation increases the risk of cardiovascular disease in patients with rheumatoid arthritis]. Troelsen LN; Jacobsen S Ugeskr Laeger; 2006 Sep; 168(39):3304-8. PubMed ID: 17032593 [TBL] [Abstract][Full Text] [Related]
6. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. Dixon WG; Symmons DP Ann Rheum Dis; 2007 Sep; 66(9):1132-6. PubMed ID: 17251223 [TBL] [Abstract][Full Text] [Related]
7. Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review. Giollo A; Bissell LA; Buch MH Expert Opin Drug Saf; 2018 Jul; 17(7):697-708. PubMed ID: 29871535 [TBL] [Abstract][Full Text] [Related]
8. New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis. Mahmoudi M; Aslani S; Fadaei R; Jamshidi AR Int J Rheum Dis; 2017 Mar; 20(3):287-297. PubMed ID: 28205331 [TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Risk in Rheumatoid Arthritis and Mechanistic Links: From Pathophysiology to Treatment. Fragoulis GE; Panayotidis I; Nikiphorou E Curr Vasc Pharmacol; 2020; 18(5):431-446. PubMed ID: 31258091 [TBL] [Abstract][Full Text] [Related]
10. Reducing the cardiovascular disease burden in rheumatoid arthritis. Van Doornum S; Jennings GL; Wicks IP Med J Aust; 2006 Mar; 184(6):287-90. PubMed ID: 16548834 [TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Avouac J; Allanore Y Expert Opin Pharmacother; 2008 May; 9(7):1121-8. PubMed ID: 18422470 [TBL] [Abstract][Full Text] [Related]
12. Atherosclerosis is not accelerated in rheumatoid arthritis of low activity or remission, regardless of antirheumatic treatment modalities. Arida A; Protogerou AD; Konstantonis G; Fragiadaki K; Kitas GD; Sfikakis PP Rheumatology (Oxford); 2017 Jun; 56(6):934-939. PubMed ID: 28160488 [TBL] [Abstract][Full Text] [Related]
13. Cytokines as therapeutic targets to reduce cardiovascular risk in chronic inflammation. Miller AM; McInnes IB Curr Pharm Des; 2011; 17(1):1-8. PubMed ID: 21222645 [TBL] [Abstract][Full Text] [Related]